TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on TG Therapeutics, with six buys, one hold, and two sells. The average 12-month price target is $63, above the stock’s reported $57.43 opening price.
• TG Therapeutics reported quarterly revenue of $240.34 million, up 70.2% year over year and ahead of estimates, but earnings per share of $0.05 missed the $0.31 consensus forecast.
• Institutional investors own 58.58% of the company, while insider ownership stands at 8.87%; director Laurence Charney recently sold 5,000 shares at an average price of $54.96.

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have earned an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $63.00.

TGTX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Zacks Research cut TG Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, September 7th. Jefferies Financial Group reissued a "buy" rating and set a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, B. Riley Financial lifted their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a report on Monday, July 27th.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares of the company's stock, valued at $9,268,454.40. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 8.87% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company's stock worth $48,544,000 after purchasing an additional 610,195 shares in the last quarter. Deutsche Bank AG acquired a new stake in TG Therapeutics in the 2nd quarter valued at about $12,937,000. Hsbc Holdings PLC raised its position in TG Therapeutics by 228.7% in the 4th quarter. Hsbc Holdings PLC now owns 146,087 shares of the biopharmaceutical company's stock valued at $4,374,000 after purchasing an additional 101,646 shares in the last quarter. PDT Partners LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $2,285,000. Finally, Jupiter Topco LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $5,319,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Down 0.2%

Shares of TGTX opened at $57.43 on Friday. TG Therapeutics has a 52-week low of $26.76 and a 52-week high of $59.30. The company has a market capitalization of $8.79 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 2.46 and a beta of 1.67. The stock has a fifty day simple moving average of $53.63 and a two-hundred day simple moving average of $45.53. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The firm had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same period in the previous year, the firm posted $0.17 EPS. The company's revenue was up 70.2% compared to the same quarter last year. As a group, equities analysts forecast that TG Therapeutics will post 0.92 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company's research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics' principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.